Hagerty Q1 2026 slides: strategic shift drives growth amid transition costs

Hagerty reported Q1 2026 revenue of $312 million and a $13 million net loss, but adjusted EBITDA rose 77% year over year to $85 million and written premium increased 18% to $289 million. Results were weighed down by $89 million of pre-tax transitional costs tied to the new Markel fronting arrangement, while management guided 2026 adjusted EBITDA to $236 million-$247 million on 15%-16% written premium growth. The stock fell about 3% as investors focused on near-term earnings pressure despite stronger underlying operating performance.

Analysis

The market is likely overreacting to the reported loss because the core story is not deteriorating economics, it is an earnings bridge from commission-heavy optics to a higher-retention balance sheet model. The key second-order effect is that Hagerty is now much more levered to its own underwriting decisions: if loss ratios hold in the high-30s, the incremental premium retention should translate into materially better operating leverage over the next 2-3 quarters once the transition charges roll off.

The real risk is not the Q1 loss itself; it is whether growth-quality holds as the company scales into more mainstream enthusiast vehicles. That expands the TAM, but it also invites a different competitive set and potentially worse pricing discipline over time. If retention stays near the current level while agent distribution and the State Farm channel ramp, the equity should re-rate on forward EBITDA rather than GAAP earnings, which makes the next two quarters the key validation window.

MKL is a subtle beneficiary here even though the arrangement compresses its economics. The lower-friction fronting model reduces operational complexity and should be margin-accretive to MKL’s fee-based capital-light portfolio, but the bigger takeaway is that Hagerty is effectively internalizing more profit pools and more risk. That creates a cleaner long-term story, but it also means any adverse severity trend or claims inflation will now hit reported results faster and harder than before.

Consensus is underappreciating the asymmetry: the downside is mostly timing-related, while the upside is multiple expansion if adjusted EBITDA keeps compounding into 2026 and reported losses shrink each quarter. This is the kind of setup where the stock can remain cheap until a single quarter shows the transition costs peaking and EBITDA staying resilient, at which point the re-rating can be abrupt.

Key Decisions for Investors

• Long HGTY over 3-6 months on post-transition normalization; risk/reward improves if Q2/Q3 show sequential EBITDA stability and declining transitional costs. Use any move below recent lows as the entry zone, with downside capped by the already-depressed valuation but upside driven by forward earnings re-rating.
• Sell out-of-the-money HGTY puts into weakness for the next 1-2 quarters if implied volatility stays elevated; the premium should compensate for the mostly calendar-driven earnings pressure while expressing a bullish bias on the transition completing on schedule.
• Pair trade: long HGTY / short a slower-growth specialty insurer with similar valuation but no comparable retention uplift catalyst over 3-6 months. The thesis is that HGTY’s earnings inflection is more visible once transition noise fades, while the short leg lacks a structural catalyst.
• Small tactical long MKL vs. a broad market basket for 1-3 months; the fronting relationship is not a major earnings driver, but it reinforces MKL’s capital-light fee stream and reduces execution complexity. Keep sizing modest because the direct economic impact is limited.
• If HGTY rallies hard before the next earnings print, trim and wait for confirmation rather than chasing; the stock is likely to trade on proof, not narrative, until the market sees two clean quarters of post-transition execution.